EUCTR2017-000621-12-Outside-EU/EEA进行中（未招募）1 期
A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent of parent(s) or guardian(s)
- •2. Genetic documentation of 5q SMA homozygous gene deletion or mutation
- •3. Onset of clinical signs and symptoms consistent with SMA at = 21 days and = 6 months (180 days) of age
- •4. Males and females between = 21 days and = 7 months (210 days) of age at Screening
- •5. At study entry, receiving adequate nutrition and hydration (with or without gastrostomy), in the opinion of the Site Investigator
- •6. Body weight > 5th percentile for age using CDC guidelines
- •7. Medical care meets and is expected to continue to meet guidelines set out in the Consensus Statement for Standard of Care in SMA (Wang et al. 2007), in the opinion of the Site Investigator
- •8. Gestational age of 35 to 42 weeks and gestation body weight = 2 kg
- •9. Reside within approximately 9 hours ground-travel distance from a participating study center for the duration of the study. Residence > 2 hours ground-travel distance from a study center must obtain clearance from the Site Investigator and the study Medical Monitor
- •10. Able to complete all study procedures, measurements and visits and parent or guardian/subject has adequately supportive psychosocial circumstances, in the opinion of the Site Investigator
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Hypoxemia (O2 saturation awake < 96% or O2 saturation asleep < 96%, without ventilation support)
- •2. Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period
- •3. History of brain or spinal cord disease that would interfere with the LP procedures, CSF circulation, or safety assessments
- •4. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter
- •5. History of bacterial meningitis
- •6. Clinically significant abnormalities in hematology or clinical chemistry parameters, as assessed by the Site Investigator, at screening that would render the subject unsuitable for inclusion
- •7. Treatment with another investigational drug (e.g., albuterol, riluzole, carnitine, creatine, sodium phenylbutyrate, salbutamol, valproate, hydroxyurea, etc.), biological agent, or device within 90 days prior to enrollment or anytime during the study. Any history of gene therapy or cell transplantation
- •8. The subject’s parent(s) or legal guardian(s) is unable to understand the nature, scope, and possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments
- •9. Ongoing medical condition that according to the Site Investigator would interfere with the conduct and assessments of the study. Examples are medical disability other than SMA that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures
研究者
相似试验
尚未招募
2 期
A Study of kultha tea in kidney stoneCTRI/2020/05/025246Ravi Kant
进行中（未招募）
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004098-33-DKBiogen Idec Research Limited183
进行中（未招募）
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004098-33-PLBiogen Idec Research Limited183
进行中（未招募）
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004098-33-SEBiogen Idec Research Limited144
进行中（未招募）
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)EUCTR2015-004098-33-DEBiogen Idec Research Limited178